SCHEMBL30765635

SCHEMBL30765635

CC(=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.79
RAB9A P51151 3/20 0.79
TTR P02766 2/20 0.57
BCAT1 P54687 6/20 0.52
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
HPGD P15428 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 2/20 0.49
MAOB P27338 1/20 0.49
IDO1 P14902 2/20 0.48
RXFP1 Q9HBX9 1/20 0.48
HTR2B P41595 1/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1283826 1.00 NPC1 (0.79) NPC1RAB9ATTRBCAT1ALDH1A1
SCHEMBL26304440 0.97 NPC1 (0.74) NPC1RAB9ATTRBCAT1ALDH1A1
SCHEMBL26317209 0.95 NPC1 (0.72) NPC1RAB9ATTRBCAT1ALDH1A1
SCHEMBL2043165 0.91 NPC1 (0.69) NPC1RAB9ATTRALDH1A1MAPT
SCHEMBL26304441 0.90 NPC1 (0.65) NPC1RAB9ATTRALDH1A1MAPT
SCHEMBL26317244 0.90 NPC1 (0.74) NPC1RAB9ATTRBCAT1ALDH1A1
SCHEMBL7110522 0.89 NPC1 (0.69) NPC1RAB9ATTRALDH1A1MAPT
SCHEMBL10882826 0.88 NPC1 (1.00) NPC1RAB9ATTRALDH1A1MAPT
SCHEMBL11285410 0.87 NPC1 (0.70) NPC1RAB9ATTRBCAT1ALDH1A1
SCHEMBL26317317 0.86 NPC1 (0.65) NPC1RAB9ATTRBCAT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed